Osiris Therapeutics, Inc.  

(Public, NASDAQ:OSIR)   Watch this stock  
Find more results for OSIR
-0.12 (-1.16%)
After Hours: 10.26 0.00 (0.00%)
Nov 30, 5:36PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 10.03 - 10.53
52 week 9.80 - 23.67
Open 10.53
Vol / Avg. 258,992.00/338,861.00
Mkt cap 357.27M
P/E 208.28
Div/yield 0.20
EPS 0.05
Shares 34.45M
Beta 0.73
Inst. own 44%
Dec 1, 2015
Osiris Therapeutics Inc at Piper Jaffray Healthcare Conference - 9:30AM EST - Add to calendar
Nov 19, 2015
Osiris Therapeutics Inc at Canaccord Genuity Medical Technology & Diagnostics Forum
Nov 16, 2015
Osiris Therapeutics Inc at Brean Capital Life Sciences Summit Conference
Nov 6, 2015
Q3 2015 Osiris Therapeutics Inc Earnings Release
Nov 6, 2015
Q3 2015 Osiris Therapeutics Inc Earnings Call
Oct 8, 2015
Osiris Therapeutics Inc at Alliance for Regenerative Medicine (ARM) Stem Cell Meeting on the Mesa
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin -2.60% -0.41%
Operating margin 1.22% 2.87%
EBITD margin - 4.44%
Return on average assets -2.59% -0.26%
Return on average equity -3.13% -0.30%
Employees 211 -
CDP Score - -


7015 Albert Einstein Drive
United States - Map
+1-443-5451800 (Phone)
+1-443-5451701 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Osiris Therapeutics, Inc. is a medical products company. The Company is focused on developing and marketing products in regenerative medicine, including bioengineering, stem cell research and viable tissue based products. The Company's offers products in orthopedics, sports medicine and wound care, including Cartiform, BIO4 and Grafix. Cartiform is a viable chondral allograft containing viable chondrocytes, chondrogenic growth factors, and extracellular matrix proteins within the intact architecture of healthy hyaline cartilage. BIO4 is a bone allograft that contains both viable cells and growth factors. It is a safe alternative to autograft that minimizes the potential for harvest site co-morbidities. Grafix is a cryopreserved placental membrane that preserves the native properties and inherent functionality of the tissue.

Officers and directors

Peter Friedli Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Lode Debrabandere Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
Gregory I. Law Chief Financial Officer, Corporate Secretary and Treasurer
Age: 48
Bio & Compensation  - Reuters
Frank D. Czworka Jr. Vice President, General Manager of Wound Care
Age: 46
Bio & Compensation  - Reuters
Adrian P. Mollo General Counsel
Age: 40
Bio & Compensation  - Reuters
Alla N. Danilkovitch Ph.D. Chief Scientific Officer
Age: 51
Bio & Compensation  - Reuters
Jonathan Mark Hopper Chief Medical Officer
Age: 52
Bio & Compensation  - Reuters
Dwayne Montgomery Chief Business Officer
Age: 47
Bio & Compensation  - Reuters
Hans-Georg Klingemann M.D., Ph.D. Independent Director
Age: 65
Bio & Compensation  - Reuters
Jay M. Moyes Independent Director
Age: 61
Bio & Compensation  - Reuters